DEA Collects $12.3 Million in Medical Marijuana Application Fees Under Trump’s Rescheduling Order

The Drug Enforcement Administration (DEA) has collected an estimated $12.3 million in registration fees from medical marijuana businesses applying for federal authorization under President Donald Trump’s partial marijuana rescheduling order, according to an analysis by The Marijuana Herald.

The estimate is based on 6,983 application entries included in the DEA’s newly released applicant list, dated October 30, including 4,197 dispensary applications, 2,076 manufacturer applications and 710 distributor applications, and the federal fees businesses are required to pay when submitting their applications.

Under the DEA’s registration fee schedule, manufacturers pay $3,699 annually, while distributors pay $1,850 annually. Medical marijuana dispensaries are subject to a separate $794 annual application fee through the agency’s specialized registration process.

Applying those fees to the application totals produces an estimated $12,325,042 in federal registration fee revenue.

Manufacturers account for the largest portion of that amount, with 2,076 applications generating an estimated $7.68 million. Dispensaries account for another $3.33 million, while distributor applications represent approximately $1.31 million.

Although dispensaries make up approximately 60% of the applications, manufacturers account for more than 62% of the estimated revenue because of their substantially higher registration costs.

The fees are generally nonrefundable and must be paid as part of the application process, regardless of whether a business ultimately receives federal registration. While the DEA has not released an official accounting of the money collected, the required fees and publicly available application figures provide a basis for estimating the revenue generated. Government exemptions and limited refunds could affect the precise amount.

The agency also explains on its website that the applicant list is updated daily and that entries may be removed when applicants receive registrations, withdraw their applications or otherwise lose their timely-applicant status. Consequently, the publicly released records do not necessarily represent every application submitted since the registration process began, meaning total fee collections could be higher than the estimate.

The registration process was established through an April 28 federal rule that moved marijuana covered by qualifying state medical marijuana licenses, along with FDA-approved marijuana products, from Schedule I to Schedule III of the Controlled Substances Act.

Businesses that applied within the initial 60-day window qualified for expedited consideration and were allowed to continue operating under their state medical marijuana licenses while their federal applications remained pending.

The rule directed DEA to make every effort to process those applications within six months of publication, a period that ended October 28. However, submitting an application does not guarantee federal approval, and businesses must still satisfy applicable registration requirements.